BIOCARDIA, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.366 USD | -2.92% |
|
-6.28% | -44.99% |
| Mar. 27 | Transcript : BioCardia, Inc., 2023 Earnings Call, Mar 27, 2024 | |
| Mar. 27 | BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
| Sales 2024 * | 700K | Sales 2025 * | 700K | Capitalization | 10.13M |
|---|---|---|---|---|---|
| Net income 2024 * | -15M | Net income 2025 * | -19M | EV / Sales 2024 * | 14.5 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 14.5 x |
| P/E ratio 2024 * |
-0.9
x | P/E ratio 2025 * |
-0.77
x | Employees | 18 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 66.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioCardia, Inc.
More press releases
| 1 day | +2.42% | ||
| 1 week | -1.62% | ||
| Current month | -7.37% | ||
| 1 month | -2.41% | ||
| 3 months | -34.47% | ||
| 6 months | -6.41% | ||
| Current year | -43.24% |
1 week
0.36
0.40
1 month
0.360.43
Current year
0.360.72
1 year
0.362.92
3 years
0.365.10
5 years
0.0017.50
10 years
0.00138.24
| Managers | Title | Age | Since |
|---|---|---|---|
Peter Altman
CEO | Chief Executive Officer | 57 | 01-12-31 |
David McClung
DFI | Director of Finance/CFO | 61 | 13-08-31 |
| Chief Tech/Sci/R&D Officer | - | 17-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Simon Stertzer
BRD | Director/Board Member | 88 | 01-12-31 |
Jay Moyes
BRD | Director/Board Member | 70 | 10-12-31 |
Richard Krasno
BRD | Director/Board Member | 82 | 16-10-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.3654 | -3.08% | 48 474 |
| 24-04-18 | 0.377 | +2.42% | 62,015 |
| 24-04-17 | 0.3681 | +1.07% | 31,758 |
| 24-04-16 | 0.3642 | -2.52% | 105,239 |
| 24-04-15 | 0.3736 | -4.18% | 117,285 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.377
USD
Average target price
4
USD
Spread / Average Target
+961.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -43.24% | 10.13M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -1.43% | 21.66B | |
| -18.35% | 20.77B | |
| -8.72% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- BCDA Stock
